Fortress Biotech Inc Pref Share FBIOP
News
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $13.75
- Day Range
- $13.36–13.80
- 52-Week Range
- $6.50–21.43
- Bid/Ask
- $13.68 / $13.80
- Shares Outstanding
- —
- Market Cap
- $46.61M
- Volume/Avg
- 25,271 / 12,774
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 78
Valuation
Metric | FBIOP |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | FBIOP |
|---|---|
Quick Ratio | 2.78 |
Current Ratio | 2.93 |
Interest Coverage | 21.79 |
Quick Ratio
FBIOP
Profitability
Metric | FBIOP |
|---|---|
Return on Assets (Normalized) | 49.10% |
Return on Equity (Normalized) | 109.53% |
Return on Invested Capital (Normalized) | 65.68% |
Return on Assets
FBIOP
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|lsWcz& | LOCK|Q%db | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|JR@KC^ | LOCK|z#c$& | $96B | |||
| Moderna Inc MRNA | LOCK|%Q%Q%dH | LOCK|jw | $81B | |||
| argenx SE ADR ARGX | LOCK|^^&#^^ | LOCK|%m | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$Q>bMhd | LOCK|Ws | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|w&%TlVWm | LOCK|Pq&m% | $30B | |||
| Incyte Corp INCY | LOCK|<m^rM&z | LOCK|?$t | $24B | |||
| BioNTech SE ADR BNTX | LOCK|>D!Rxb | LOCK|R! | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!<^Y?t | LOCK|G^Ftd | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|!hW?TF | LOCK|Dz | $15B |